Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSD2 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
LSD2 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of lysine-specific demethylase 2 (LSD2, also known as KDM1B). LSD2 is a flavin-dependent histone demethylase that specifically demethylates mono- and di-methylated histone H3 lysine 4 (H3K4me1/2) and lysine 9 (H3K9me1/2), playing a key role in chromatin remodeling and transcriptional regulation. In preclinical research, particularly in breast cancer models, transient knockdown of LSD2 using siRNA has been shown to significantly inhibit cell proliferation and growth in multiple breast cancer cell lines, suggesting that LSD2 is a potential therapeutic target for oncology indications.
- Other names
- KDM1B siRNAKDM-1B siRNAKDM 1B siRNALSD2 small interfering RNALSD-2 small interfering RNALSD 2 small interfering RNAlysine-specific demethylase 2 siRNAlysine-specific histone demethylase 1B siRNA
02
Targets
KDM1B (KDM1B / LSD2)
Beyond the preview
Go deeper on LSD2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSD2 siRNA.